Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibiotics to treat the serious and life-threatening multidrug-resistant infections that pose a major and growing global health threat. Tetraphase’s proprietary breakthrough chemistry technology enables the design of molecules that can overcome antibiotic resistance. Our drug platform has led to the creation of more than 3,000 broad- and selective-spectrum antibiotic drug candidates. Tetraphase common stock trades under the NASDAQ symbol ‘TTPH.’ Tetraphase is well positioned to be a major player in the multidrug-resistant arena.
Tetraphase Pharmaceuticals was founded in 2006 and is headquartered in Watertown, US
Key People at Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals Locations
Tetraphase Pharmaceuticals Metrics
Tetraphase Pharmaceuticals Summary
Closing share price
Tetraphase Pharmaceuticals's current market capitalization is $157 M.
Tetraphase Pharmaceuticals Financials
Tetraphase Pharmaceuticals's revenue is $9.1 M in FY, 2014 which is 50.21% decrease from the previous period.
Operating expense total
Operating cash flow
Tetraphase Pharmaceuticals Market Value History
We estimate that Tetraphase Pharmaceuticals's current employees are approximately 6% female and 94% male.
Market Position – Health, clinics, platform, pharma